LSDI Stock: Will Lucy Scientific Discovery (NASDAQ:LSDI) Come Back?

Listing of a stock on a major exchange is often seen as a positive by investors but it may not always go to plan for the companies involved and that is what happened with the Lucy Scientific Discovery (NASDAQ:LSDI) or LSDI stock on Thursday.

The company, which is involved in the contract manufacturing of compounds meant for psychotropic and psychedelic therapies, was listed on the NASDAQ on Thursday. The stock performed poorly and slid by as much as 25% on the first day of trading.

Lucy Scientific Discovery

Company Name: Lucy Scientific Discovery

Ticker: LSDI

Exchange: NASDAQ


Lucy Scientific Discovery Summary:

 Lucy Scientific Discovery Inc. researches develop, manufactures, and commercializes psychedelic products. It offers biological raw materials, crude extracts, psychotropic compounds, and active pharmaceutical ingredients (APIs). Lucy Scientific Discovery Inc. was formerly known as Hollyweed North Cannabis, Inc. The company was incorporated in 2017 and is based in Victoria, Canada.

Here are the top 3 catalysts for LSDI stock.

#1 LSDI Stock Falls In Debut Trading

The initial public offering made by the company on NASDAQ was worth as much as $7.5 million. LSDI stock opened trading at $4 a share but eventually slumped to $2.89 each before ending the day at $2.99 a share.

The company offered as many as 1.87 million shares in the initial public offering for $4 each. The underwriters for the offering had also been provided with a 45-day option for picking up, more shares in the company.

#2 Downsized IPO again

The sole book runner for the company is WestPark. In light of the poor performance on listing day, it is perhaps important for investors to keep in mind that back in December last year, the company had actually reduced the size of its IPO for LSDI stock.

Initially, the size of the IPO had been supposed to be $10 million but Lucy had decided to reduce it to $8 million.

#3 Moderate Industry Growth

While the performance on the listing day may come as a dampener for the company, its shareholders, and potential investors, it ought to be noted that Lucy is involved in an industry that is geared for growth.

As per research conducted by Future Market Insights, the psychotropic drugs market is expected to grow at a rate of 6% CAGR over the course of the period between 2022 and 2032. There is significant awareness now with regard to mental health conditions and the introduction of safe psychotropic treatments could well be the way forward in the coming years.

LSDI stock could be on your watchlist this month it is trading in the oversold zone.


Small Cap Exclusive is owned and operated by King Tide Media, LLC, which is a US based corporation & has been compensated $350,000 from Lucy Scientific Discovery Inc. for profiling LSDI. We own ZERO shares in LSDI. Full Disclaimer

Therma Bright Inc (TSXV:THRM) (OTCQB:TBRIF) Signs The Exclusive Worldwide Licensing Rights To Market And Sell Ai4lyf’s Digital Cough Technology (Dct)


The medical devices industry has grown at a decent clip over the course of the past years and one of the companies which could be worth looking into at this point is Therma Bright Inc (TSXV:THRM) (OTCQB:TBRIF). The company is currently best known for having developed the smart-enabled AcuVid COVID-19 Rapid Antigen Saliva Test but it has been working on other devices as well.

This morning the company has come into the news cycle after it announced that it had inked the exclusive global licensing rights to sell and market AI4LYF’s Digital Cough Technology (DCT). It was another major development for the company and one that is expected to bring Therma Bright onto the radars of investors.

The most important thing to point out with regard to DCT is the fact that the technology can help in detecting a range of respiratory diseases instantly and that includes COVID-19. The technology is deployed through a smartphone application and it can work anywhere at any time.

More importantly, the exclusive license is particularly important for Therma Bright. That would allow the company to work on the development of DCT solutions for detecting other diseases like bronchiolitis, asthma, and pneumonia among others.

It goes without saying that the latest development could well be a significant one for Therma Bright and investors could consider keeping an eye on the stock. Back in November 2022, it had been announced that the patent-pending DCT solutions was a revolutionary technology, powered by an artificial intelligence engine, which could change the way respiratory diseases were detected.

For instance, the app can come up with a result for the COVID-19 test within a minute and more importantly, it has managed to clock an accuracy rate of as much as 94%.

Small Cap Exclusive is owned and operated by King Tide Media, which is a US based corporation has been compensated $60,000 from Therma Bright Inc for profiling TBRIF for 30 days starting Feb 21 2023. We own ZERO shares in TBRIF.

Lordstown Motors: RIDE Stock Gains Momentum: But Why?

Electric vehicle manufacturing company Lordstown Motors Corp (NASDAQ:RIDE) is one of the companies to have come into sharp focus among investors in recent days and that can be gauged from the price action in the RIDE stock.

Over the course of the past week, the stock has managed to clock gains of 18% and that took the gains over the past month to as much as 25%. While it is currently trading above its key averages, it should not be forgotten that it is still down by 45% in the past six months.

Lordstown Motors Corp

Company Name: Lordstown Motors Corp

Ticker: RIDE

Exchange: NASDAQ


Lordstown Motors Corp Summary:

Lordstown Motors Corp. develops, manufactures, and sells Endurance, an electric full-size pickup truck for fleet customers. The company was founded in 2019 and is based in Lordstown, Ohio.

Let’s take a look at the company’s recent news and developments of RIDE stock:-

#1 Expects Slow Rate Of Production in 1Q

The company had actually been in the news in recent times and came up with a key update back on January 4, 2023. At the time it announced that the rate of production in the first quarter was going to be slow owing to supply chain issues.

The company sent in a filing to the United States Securities and Exchange Commission in which it noted that the main supply chain problem was related to hub motor components availability. It was in the third quarter of 2022 that the company started the production of its Endurance pickup truck.

RIDE stock reacted positively after the news.

#2 Starts Shipping First Endurance Trucks To Customers

Last, in the month of January the company was in the news once again after it announced on January 11 that it had started shipping its first batch of Endurance pickup trucks to its customers.

At the time it was also announced by Lordstown Motors that the Endurance pickup truck had been named one of the three finalists in the North American Truck of the Year event for 2023.

#3 LEVs Market Projected To See a CAGR of 9.4%

While these are significant developments, it is perhaps most important for investors to keep in mind that Lordstown Motors is involved in an industry with the potential for significant growth. The light electric vehicle market is expected to have a valuation of $122.7 billion by 2027 from only $78.5 billion in 2022.

Keep an eye on RIDE stock as it is consolidating after the recent jump.

FLGC Stock: Flora Growth (NASDAQ:FLGC) Gains Momentum On Revenue Growth: Will It Sustain?

A stock that has managed to come onto the surface following a strong move over the course of the past few days is FLGC stock. Flora Growth Corp (NASDAQ:FLGC), which is involved in the outdoor cultivation, manufacturing, and distribution of cannabis products, was in the news earlier on in the week.

Flora Growth Corp

Company Name: Flora Growth Corp

Ticker: FLGC

Exchange: NASDAQ


Flora Growth Corp Summary:

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands designed to deliver the most compelling customer experiences in the world, one community at a time.

As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions.

Now, let’s analyze the latest news from FLGC stock:-

#1 Expects 100% Topline Growth For Fiscal 2023

On Monday the company announced that it expected its revenues for the fiscal year of 2023 to be in the $90 million to $105 million range. It was a significant new announcement from the company and on the day of the announcement the stock clocked gains of as much as 40%. In this regard, it should also be noted that a survey by FactSet expected the company to post revenues of $95.6 million for the year.

The company included the revenues that were projected from its new acquisition Franchise Global Health, a Germany-based business, in its projections.

FLGC stock reacted bullishly after the news.

#2 Gets Additional 180 Day Extension by Nasdaq to Regain Compliance

Earlier on in the month of January 2023, the company had come into the news once again after it announced that it had got an extension of 180 days from NASDAQ so as to fulfill the $1 minimum bid price requirement that is part of the listing rules of the exchange.

The initial period of 180 days to regain compliance expired back on January 4, 2023. The extension could be construed as a positive development for the company as it tries to stay listed on the exchange.

#3 Acquisition of Franchise Global Health

The acquisition of Franchise Global Health, which had been completed in December last year could well be a cornerstone for the company’s growth.

Thanks to the acquisition the company is going to establish a presence in the fast-growing German market and sell medical cannabis through more than 1200 pharmacies as well as distribution outlets spread across 28 nations. Franchise Global Health generated a gross profit of C$2.8 million and revenues of C$42 million in the nine-month period that ended on September 30, 2022.

After the recent rally, the stock might find resistance at a higher lever, and profit booking may be healthy for now.

Take a look at the CIFR stock, which is flying after a key update.

CIFR Stock: Cipher Mining (NASDAQ:CIFR) Tripled This Year: How Far Can It Go? — Copy

Stocks that bounce back in a big way after having gone through a tough period are almost always of interest to investors and a stock that fits that particular bill is that of CIFR stock.

Last year, the Cipher Mining Inc (NASDAQ:CIFR) stock had gone through a slump but it has managed to go on a remarkable recovery in the New Year and so far in 2023, it has clocked gains of as much as 200%.

Cipher Mining Inc

Company Name: Cipher Mining Inc

Ticker: CIFR

Exchange: NASDAQ


Cipher Mining Inc Summary:

Cipher is an emerging technology company focused on the development and operation of bitcoin mining data centers in the United States. Cipher is dedicated to expanding and strengthening the Bitcoin network’s critical infrastructure.

Together with its diversely talented team and strategic partnerships, Cipher aims to be a market leader in bitcoin mining growth and innovation.

Now, let’s analyze the latest news from CIFR stock:-

#1 January 2023 Operational Update

The company is involved in the development and operation of Bitcoin mining data centers and yesterday, it came into the news cycle after it announced its operations and production update for the month of January 2023. It should be noted that the numbers released by Cipher Mining were unaudited.

The company announced that it mined 343 Bitcoin tokens and sold 314 of those for the month, at the end of which it still held 424 Bitcoin tokens. The hash rate at the end of the month stood at 4.3 EH/s.

The company’s management noted that during the month Cipher continued to broaden its operations from out of Odessa, financed more capital expenditure, and built its Bitcoin inventory. At the start of the month, the company had the mining capability of 9.3 Bitcoin tokens a day but by the end of the month, it stood at 14 Bitcoin tokens a day. That reflected a rise of almost 51% in a matter of one month.

The CIFR stock has reacted positively after the update.

#2 Expands Operations at Odessa Data Center

Back on December 20, 2022, the company had been in the news after it announced that it got more mining rigs that were going to be installed at the Odessa data center that had been opened recently. The self-mining rate of the company was going to go up to 6 EH/s following the move.

#3 Stock Hits Multi-Month High On Solid Momentum

Last year, the stock had gone through a slump but it has managed to go on a remarkable recovery in the New Year and so far in 2023, it has clocked gains of as much as 200%.

The CIFR stock has recorded healthy trading volumes in 2023 so far and has been trading higher than all moving averages including 20-day and 50-day.

Following the recent momentum, the CIFR stock may continue to be an interesting play and we may see buying on every dip for the short term.  

Don’t forget to get inside on OPEN stock Here

OPEN Stock: Opendoor Technologies Inc (NASDAQ:OPEN) Bounces Back: Will It Continue?

Residential real estate transaction platform operator Opendoor Technologies Inc (NASDAQ:OPEN) is one of the more innovative companies at the moment and the OPEN stock has been in the middle of a strong ride in recent weeks. The stock has continued to climb in the past week during the course of which it went up by 38%.

That took the gains made in the past month to as much as 98% as the OPEN stock ended up hitting its highest level in many months.

Opendoor Technologies Inc

Company Name: Opendoor Technologies Inc

Ticker: OPEN

Exchange: NASDAQ


Opendoor Technologies Inc Summary:

Opendoor Technologies Inc. operates a digital platform for residential real estate in the United States. The company’s platform enables consumers to buy and sell a home online. It also provides title insurance and escrow services. Opendoor Technologies Inc. was incorporated in 2013 and is based in Tempe, Arizona.

Now, let’s review the latest news from the company:-

#1 Q4 Earnings On Radar – All eyes on OPEN stock

All eyes are now going to be on the company’s fourth-quarter financial results and it may be a good time to keep an eye on the Opendoor stock in the lead-up to the day.

On January 26 the company announced that it was going to announce its financial results for the fourth fiscal quarter that ended on December 31, 2022, on February 23, 2023. On top of that, the management would also host a conference call to discuss the financial results and other operations. The conference call would be available on a live webcast at 2 pm PT.

It would be keenly watched, how the OPEN stock would react after earnings.

#2 Opendoor Shuffles Leadership, Appoints New CEO

The performance in the third quarter of Opendoor may have triggered a change in the management as well and back on December 2, 2022, the company made such an announcement. It announced that it had appointed a new Chief Executive Officer in the form of Carrie Wheeler.

Wheeler had previously been the Chief Financial Officer at Opendoor. The shakeup at the top echelons in the management had initially led to a selloff in the stock. Wheeler was also made a member of the board of directors of the company with immediate effect.

#3 Why The OPEN stock Fell Last Year

Last year, the stock had gone through a tough time as the weakness in demand and plunging home prices took their toll. In the third quarter, the company’s performance had been disappointing and that resulted in a 20% drop in the stock price. That took the cumulative loss in a 12-month period to 88%.

Keep an eye on OPEN stock and it would be interesting to see if the stock reverses its losses from the last year.

TCBP Stock: TC BioPharm (NASDAQ:TCBP) Stock On Radar Ahead of A Key Event

Clinical-stage biotech company TC BioPharm (NASDAQ:TCBP) has seen it’s stock considerable momentum over the course of the past month and it could well be a good time to start taking a deeper look into it. In the past week, TCBP stock clocked gains of 13% and that took the gains made by it over the course of the past month to as much as 40%.

The company is mainly involved in the development of platform allogeneic gamma-delta T cell therapies which are meant for treating cancer.

TC BioPharm

Company Name: TC BioPharm

Ticker: TCBP

Exchange: NASDAQ


Adamas One Corp Summary:

TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.

Here are the latest news from TCBP stock:-

#1 All Eyes On Shareholder Update Call

The company was in the news last week on January 20 when it announced that it was going to come up with a shareholder update on February 20, 2023, at 10 in the morning Eastern Standard Time.

In that particular update, the management of TC BioPharm would be looking to provide a detailed update with regard to the trial plan for the allogeneic gamma delta therapeutic in different oncology indications. There will also be a question and answer session after CFO Martin Thorp and CEO Bryan Kobel complete their remarks.

It would be interesting to see how would TCBP stock react after the event.

#2 Receives Notice of Non-compliance with NASDAQ’s Listing Rule 5550(b)(1)

On January 19, it emerged that TC BioPharm had been provided with a written notification from NASDAQ with regards to the fact that it had failed to regain compliance as per the minimum Market Value of Listed Securities threshold of $35,000,000. That figure is the minimum for continued listing on the exchange.

The company announced at the time that it was going to present the exchange with a comprehensive plan on how it was going to address the situation and regain compliance.

#3 Strategic Collaboration to Advance Gamma Delta T Cells in Oncology

Another major development with regards to TC BioPharm was the announcement from the company earlier this month on January 17 that it had decided to get into collaboration with the celebrated University of Texas MD Anderson Cancer Center.

The collaboration would be focussed on expanding the knowledge with regard to the deployment of gamma-delta T cells in oncology. It remains to be seen if TCBP stock can hold onto its momentum this week.

So, keep an eye on TCBP stock as shareholders would reach to the company’s upcoming earnings and we may see high volatility. Get more lists of stocks here

JEWL Stock: Adamas One Corp (NASDAQ:JEWL) On Watchlist After Recent Fall

Technology has influenced most industries in the world in a big way and in this regard, even the jewelry industry is no exception. In this context, it may be a good time for JEWL stock investors to look into Adamas One Corp (NASDAQ:JEWL), which has emerged as one of the more innovative companies in the industry.

The company has managed to leverage technology to create lab-created diamonds, which can be used both for making jewelry and also for industrial purposes.

Adamas One Corp

Company Name: Adamas One Corp

Ticker: JEWL

Exchange: NASDAQ


Adamas One Corp Summary:

Adamas One Corp., a diamond company, produces single crystal diamonds and diamond materials for diamond jewelry industry and industrial markets in the United States and internationally. The company was incorporated in 2018 and is based in Scottsdale, Arizona.

Here are the latest news from JEWL stock:-

 #1 Influencer TRAX NYC Visits Adamas One South Carolina Factory

Last week on January 19, the company was in the news after it announced that TRAX NYC, a jewellery influence had gone on a video tour of its facility in Greenville, South Carolina, and posted a video on Instagram.

The video had proven to be a roaring success and within the first hour it had clocked as many as 200,000 views. Such a video could often prove to be a potent marketing campaign in the age of social media and it could only be seen as a positive for Adamas One.

JEWL stock reacted muted to the news.

#2 Reports Initial Diamond Sales for Fiscal Year 2022

On January 18, the company came into the news cycle once again when it announced its financial results for the fiscal year that ended on September 30, 2022. The company noted that during that financial year, it had managed to sell as much as $1.78 million worth of its lab-grown diamonds.

That was a major turnaround considering the fact that in the previous fiscal year, the total sales had stood at $0.

#3 Newly Lists Stock – Forms Base After Recent Fall

The company started its marketing campaign in the middle of the second quarter and hence, most of the sales was closed in the final seven months of the fiscal year. That came as a significant boost as well considering the fact that Adamas One was listed on the JEWL stock market back on December 16, 2022, in an initial public offering worth $11 million.

Skip to content